FoundationOne Heme For Hematological Malignancy

FoundationOne Heme for hematological Malignancy is a comprehensive genomic profiling test (CGP) test that analyses the DNA and RNA of tumor cells to identify genetic alternations that may be driving the growth and spread of a patient’s cancer.

In the context of hematological malignancies, FoundationOne Heme can help identify specific genomic alterations that are characteristic of different types of blood cancer. These alternations may include mutations, copy number alterations, and gene fusions, which can be used to inform treatment decisions and help guide personalized treatment plans for patients.

FoundationOne Heme can also provide information on potential therapeutic targets and clinical trial opportunities, as well as insights into a patient's overall prognosis and potential risk for relapse.

Why is FoundationOne Heme for hematological Malignancy done?

FoundationOne Heme is done for patients with hematological malignancies such as leukemia, lymphoma, and myeloma, to identify genetic alterations that may be driving the growth and spread of their cancer. The test uses advanced genomic sequencing technology to analyze the DNA and RNA of tumor cells, identifying mutations, copy number alterations, and gene fusions that are characteristic of different types of blood cancers.

The information provided by FoundationOne Heme can help clinicians and oncologists to:

Personalize treatment: By identifying the specific genetic alterations driving a patient's cancer, clinicians can develop a personalized treatment plan tailored to the unique needs of the patient. For example, they can identify targeted therapies that may be more effective for a particular patient based on their genomic profile.

Predict prognosis: Certain genomic alterations have been linked to specific prognoses for different types of hematological malignancies. FoundationOne Heme can help identify these alterations, allowing clinicians to predict a patient's prognosis and develop a treatment plan accordingly.

Identify clinical trial opportunities: FoundationOne Heme can identify specific genomic alterations that may make a patient eligible for certain clinical trials, which can offer access to new and innovative treatments that are not yet widely available.

Sample Type Required

>>Peripheral blood and bone marrow

Cost of FoundationOne Heme for hematological Malignancy

The cost of FoundationOne Heme for hematological Malignancy near me in Delhi ranges from INR 200000 to INR 500000